Palvella Therapeutics
PVLA
49 hedge funds and large institutions have $8.04M invested in Palvella Therapeutics in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 17 reducing their positions, and 17 closing their positions.
2,000% more call options, than puts
Call options by funds: $21K | Put options by funds: $1K
0.17% more ownership
Funds ownership: 0.58% → 0.74% (+0.17%)
18% less funds holding
Funds holding: 60 → 49 (-11)
59% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 17
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
76% less capital invested
Capital invested by funds: $33.4M → $8.04M (-$25.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$11.8M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$4.77M |
| 3 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$2.05M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$729K |
| 5 |
CM
CM Management
Gulf Breeze,
Florida
|
+$417K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.04M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$2.22M |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$952K |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$947K |
| 5 |
Walleye Capital
New York
|
-$467K |
PVLA Hedge Fund Activity: Q2 2023 in Review
49 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2023, worth a combined $8.04M — down 76% from $33.4M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of PVLA and 6 opened new positions — a net loss of 11 holders — while 17 trimmed existing stakes and 7 added.
The largest buyer was BVF Inc, adding an estimated $11.8M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $4.04M sold.
- 49 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2023, down from 60 in Q1 2023.
- Funds reported $8.04M of Palvella Therapeutics stock for Q2 2023, down 76% quarter-over-quarter.
- 6 funds opened new Palvella Therapeutics positions in Q2 2023 and 17 closed out, a net change of -11 holders.
- The largest Palvella Therapeutics buyer in Q2 2023 was BVF Inc, an estimated $11.8M added.
- The largest Palvella Therapeutics seller in Q2 2023 was Soleus Capital Management, an estimated $4.04M sold.
Based on aggregated 13F filings for Q2 2023.